NT-proBNP trajectory after transcatheter aortic valve replacement and its association with 5-year clinical outcomes.
NT-proBNP
aortic stenosis
prognosis
trajectory
transcatheter aortic valve replacement
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
11
2022
accepted:
06
02
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
There are only limited reports on the trends of NT-proBNP after transcatheter aortic valve replacement (TAVR) in aortic stenosis (AS) and even fewer report on the prognostic value of the NT-proBNP trajectory following TAVR. This study aims to investigate short-term NT-proBNP trajectory following TAVR and explore its association with clinical outcomes in TAVR recipients. Aortic stenosis patients undergoing TAVR were included if they had NT-proBNP levels recorded at baseline, prior to discharge, and within 30 days after TAVR. We used latent class trajectory models to identify NT-proBNP trajectories based on their trends over time. Three distinct NT-proBNP trajectories were identified from 798 TAVR recipients, which were named class 1 ( Our findings implied different short-term evolution of NT-proBNP levels in TAVR recipients and its prognostic value for AS patients following TAVR. NT-proBNP trajectory may have further prognostic value, in addition to its baseline level. This may aid clinicians with regards to patient selection and risk prediction in TAVR recipients.
Sections du résumé
Background
UNASSIGNED
There are only limited reports on the trends of NT-proBNP after transcatheter aortic valve replacement (TAVR) in aortic stenosis (AS) and even fewer report on the prognostic value of the NT-proBNP trajectory following TAVR.
Objectives
UNASSIGNED
This study aims to investigate short-term NT-proBNP trajectory following TAVR and explore its association with clinical outcomes in TAVR recipients.
Methods
UNASSIGNED
Aortic stenosis patients undergoing TAVR were included if they had NT-proBNP levels recorded at baseline, prior to discharge, and within 30 days after TAVR. We used latent class trajectory models to identify NT-proBNP trajectories based on their trends over time.
Results
UNASSIGNED
Three distinct NT-proBNP trajectories were identified from 798 TAVR recipients, which were named class 1 (
Conclusion
UNASSIGNED
Our findings implied different short-term evolution of NT-proBNP levels in TAVR recipients and its prognostic value for AS patients following TAVR. NT-proBNP trajectory may have further prognostic value, in addition to its baseline level. This may aid clinicians with regards to patient selection and risk prediction in TAVR recipients.
Identifiants
pubmed: 36873418
doi: 10.3389/fcvm.2023.1098764
pmc: PMC9981663
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1098764Informations de copyright
Copyright © 2023 Zhou, Zhu, Hu, Li, Lin, Liu, Pu and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Cardiol. 2015 Nov 15;116(10):1560-5
pubmed: 26428025
Heart Vessels. 2019 May;34(5):777-783
pubmed: 30443765
JAMA Cardiol. 2020 Oct 1;5(10):1123
pubmed: 32667619
Can J Cardiol. 2014 Sep;30(9):1027-34
pubmed: 25151285
Open Heart. 2018 Apr 1;5(1):e000739
pubmed: 29632678
J Am Heart Assoc. 2019 Feb 5;8(3):e010876
pubmed: 30686097
Catheter Cardiovasc Interv. 2015 Jun;85(7):1240-7
pubmed: 25511571
J Am Coll Cardiol. 2020 Apr 14;75(14):1659-1672
pubmed: 32273031
Nat Rev Cardiol. 2018 Jul;15(7):387-407
pubmed: 29674714
Eur Heart J. 2022 May 21;43(20):1952-1954
pubmed: 35301541
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013779
Rev Port Cardiol (Engl Ed). 2018 Jan;37(1):67-73
pubmed: 29317115
J Am Coll Cardiol. 2020 Dec 1;76(22):2579-2590
pubmed: 33243378
JACC Cardiovasc Interv. 2014 Jul;7(7):707-16
pubmed: 24954571
Rev Cardiovasc Med. 2022 Feb 22;23(2):75
pubmed: 35229566
JAMA Cardiol. 2022 Apr 01;7(4):435-444
pubmed: 35171199
JAMA Cardiol. 2020 Oct 1;5(10):1113-1123
pubmed: 32667623
Stat Med. 2007 May 10;26(10):2229-45
pubmed: 16900568
Am Heart J. 2001 Jun;141(6):925-32
pubmed: 11376305
Cardiovasc Diagn Ther. 2012 Jun;2(2):147-64
pubmed: 24282708
J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746
pubmed: 33888385
Am J Cardiol. 2015 May 1;115(9):1265-72
pubmed: 25863422
Eur Heart J. 2020 Feb 21;41(8):958-969
pubmed: 31883339
Eur Heart J. 2016 Jul 21;37(28):2217-25
pubmed: 26819226
Am J Cardiol. 2014 Nov 1;114(9):1447-55
pubmed: 25217456
J Mol Cell Cardiol. 2016 Aug;97:245-62
pubmed: 27262674
Am J Cardiol. 2015 Dec 15;116(12):1904-9
pubmed: 26602075
J Am Heart Assoc. 2020 Dec;9(23):e017574
pubmed: 33241754
Am J Cardiol. 2014 Mar 1;113(5):851-9
pubmed: 24528616
J Am Heart Assoc. 2022 Apr 5;11(7):e023466
pubmed: 35301869
Am J Cardiol. 2019 Mar 1;123(5):820-826
pubmed: 30587374
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811
J Mol Cell Cardiol. 2019 Apr;129:266-271
pubmed: 30878394